AIM2 has also been observed to promote PD-L1 expression, suggesting that targeting AIM2 inflammasome therapy could potentially down-regulate PD-L1 expression, thereby counteracting the immune evasion in NSCLC (Figure 3, right panels) (101, 109, 110). The gene discussed is AIM2; the disease is non-small cell lung carcinoma.